Many pharma and biotech companies are seeking new ways of making drug development more efficient and cost-effective in order to achieve their regulatory milestones faster. To meet this demand, the outsourcing services sector has scaled and grown, but in doing so, has become more siloed, with separate vendors each handling different activities – from medicinal chemistry, to preclinical studies, to clinical research, to product development and manufacturing. This separation has created a more complex approach to drug development for sponsor companies, where there is a distinct lack of communication between the multiple vendors working on a particular drug molecule, leading to delayed timelines, increased risk and higher costs.
In this presentation, our Senior Drug Development Consultant Vanessa Zann will be joined by Lynn Kirkpatrick, CEO of Ensyce Biosciences, to discuss the benefits of Quotient Sciences' integrated drug development platform Translational Pharmaceutics®. This unique approach integrates drug substance, drug product and clinical testing activities under a single program manager and single company.
Hear Lynn's first hand experience working with Quotient Sciences and utilizing Translational Pharmaceutics for their PF14-MPAR program. She will touch on why Ensysce selected Quotient Sciences as their outsourcing partner, provide an overview of their project scope, and discuss how Translational Pharmaceutics was employed to help support their corporate goals. PF614-MPAR, which is currently in Phase 1, is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences has supported Ensysce by providing an integrated formulation development and phase 1 clinical study program for PF614.
About Ensyce Biosciences
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
About Quotient Sciences:
Quotient Sciences is a drug development and manufacturing accelerator supporting customers across the entire development pathway from candidate selection to commercial launch. We deliver uniquely integrated programs and a range of tailored services that dramatically shorten drug development times. We’re driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.
www.quotientsciences.com | info@quotientsciences.com
Key Learning Objectives
- Discover how the integration of drug substance, drug product & clinical testing activities under one organization can encourage close relationships between multidisciplinary experts, creating a more agile approach to pharmaceutical development, which ultimately accelerates timelines towards IND and onwards to proof-of-concept
- Understand how drug product formulations and doses can be adjusted and manufactured in real-time, often in response to emerging human data;
- Understand why Ensysce Biosciences selected Quotient Scicences as their outsourcing partner for PF614-MPAR
- Hear how Translational Pharmaceutics has accelerated Ensysce Biosciences' drug development timeline
- Learn about overall project outcomes and what Ensysce hopes to achieve next through their partnership with Quotient Sciences
